



# GLASSIA

[Alpha<sub>1</sub>-Proteinase Inhibitor (Human)]

## Coding Reference Guide

Diagnosis Code	
Alpha-1 Antitrypsin Deficiency	273.4

NDC Code	
GLASSIA, 1mg	00944-2884-01

HCPCS Codes*	
<b>Physician Office Billing, Home Health Billing or Hospital Outpatient Department Billing (HOPPS)</b>	
INJECTION, ALPHA 1-PROTEINASE INHIBITOR (HUMAN), (GLASSIA), 10 MG	J0257
<i>The information should include the name of the biologic therapy (GLASSIA), the dose administered, the route of administration, and the national drug code (NDC code). Please check with the carrier or insurance company for specific directions. Additional documentation may be required by an individual insurance company.</i>	

Administration Codes**	
<b>Physician Office Billing or Hospital Outpatient Department Billing (HOPPS)</b>	
IV infusion for therapy, prophylaxis or diagnosis; initial, up to 1 hour	96365
IV infusion for therapy, prophylaxis or diagnosis; each additional hour (List separately in addition to code for primary procedure)	96366 (Add-on code)
IV infusion for therapy, prophylaxis or diagnosis; additional sequential infusion, up to one hour (List separately in addition to code for primary procedure)	96367 (Add-on code)
IV infusion for therapy, prophylaxis or diagnosis; concurrent infusion (List separately in addition to code for primary procedure)	96368 (Add-on code)

\* HCPCS Level II codes copyright 2010 Ingenix, Inc. All rights reserved.

\*\* CPT codes copyright 2010 American Medical Association (AMA). All rights reserved. CPT is a trademark of the AMA. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein.

Please see the Detailed Important Risk Information on back side and the enclosed Prescribing Information for full prescribing details





Alpha<sub>1</sub>-Proteinase Inhibitor (Human), GLASSIA is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha<sub>1</sub>-proteinase inhibitor (Alpha<sub>1</sub>-PI), also known as alpha<sub>1</sub>-antitrypsin (AAT) deficiency.

- The effect of augmentation therapy with GLASSIA or any Alpha<sub>1</sub>-PI product on pulmonary exacerbations and on the progression of emphysema in Alpha<sub>1</sub>-PI deficiency has not been demonstrated in randomized, controlled clinical trials.
- Clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with GLASSIA are not available.
- GLASSIA is not indicated as therapy for lung disease in patients in whom severe Alpha<sub>1</sub>-PI deficiency has not been established.

### Detailed Important Risk Information

GLASSIA is contraindicated in IgA deficient patients with antibodies against IgA. GLASSIA is contraindicated in individuals with a history of severe immediate hypersensitivity reactions, including anaphylaxis, to Alpha<sub>1</sub>-PI products.

GLASSIA is made from human plasma. It may carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Administer GLASSIA within 3 hours of entering the vials.

Administer GLASSIA at room temperature at a rate not greater than 0.04 mL/kg body weight per minute.

**If anaphylactic or severe anaphylactoid reactions occur, discontinue the infusion immediately.**

Safety and effectiveness in patients over 65 years of age have not been established.

Two serious adverse reactions observed on two separate occasions during clinical studies with GLASSIA were cholangitis and exacerbation of chronic obstructive pulmonary disease (COPD).

The most common product-related adverse reactions in clinical studies were headache and dizziness.

**Please see accompanying GLASSIA Prescribing Information.**

## **Glassia** [Alpha<sub>1</sub>-Proteinase Inhibitor (Human)]

**Baxter's GLASSIA Reimbursement Helpline (1-888-229-8379)** is available to assist with billing and coding questions or general research requests.

Information released in the HCPCS Quarterly Update page which can be retrieved on the CMS website:  
[www.cms.hhs.gov/HCPCSReleaseCodeSets/02\\_HCPCS\\_Quarterly\\_Update.asp](http://www.cms.hhs.gov/HCPCSReleaseCodeSets/02_HCPCS_Quarterly_Update.asp)

The information contained in this Coding Reference Guide is provided for informational purposes only. Every reasonable effort has been made to verify the accuracy of the information; however, this guide is not intended to provide specific guidance on how to utilize, code, bill or charge for any product or service. Healthcare providers should make the ultimate determination as to when to use a specific product based on clinical appropriateness for a particular patient. Third-party payment for medical products and services is affected by numerous factors, and Baxter cannot guarantee success in obtaining insurance payments.

Baxter is a registered trademark of Baxter International Inc.  
Glassia is a registered trademark of Kamada Ltd.

December 2011 HYL5857A 101921

**Baxter**